Dr. Arben Lasku

Publications

1.
Nelson EO, Kozin AF, Ruiz G, Lasku A, Langland JO. Treatment of Athlete’s Plantar Warts Using a Botanical Blend: A Case Report. Altern Ther Health Med. 2017 Feb 27;
2.
Mariani G, Lasku A, Pau A, Villa G, Motta C, Calcagno G, et al. A pilot pharmacokinetic and immunoscintigraphic study with the technetium-99m-labeled monoclonal antibody BC-1 directed against oncofetal fibronectin in patients with brain tumors. Cancer. 1997 Dec 15;80(12 Suppl):2484–9.
3.
Mariani G, Lasku A, Balza E, Gaggero B, Motta C, Di Luca L, et al. Tumor targeting potential of the monoclonal antibody BC-1 against oncofetal fibronectin in nude mice bearing human tumor implants. Cancer. 1997 Dec 15;80(12 Suppl):2378–84.
4.
Mariani G, Lasku A, Villa G, Motta C, Calcagno G, Taddei GZ, et al. Validation in animal models and in patients of monoclonal antibody BC-1 directed against Oncofetal Fibronectin. Journal of Nuclear Medicine. 1996;37(5):1070.
5.
Mariani G, Lasku A, Balza E, Gaggero B, Motta C. Tumor targeting potential in nude mice of the radioiodinated monoclonal antibody BC-1 directed against Oncofetal Fibronectin. European Journal of Nuclear Medicine. 1996;9:1225.
6.
Lasku A, Harasani X, Selenica G, Marku N, Leskoviku S, Buzo S. Carcinoembrionic Antigen and the prognosis of the patients with colorectal cancer. Revista Mjekesore. 1995;2:98–103.
7.
Rada F, Buzo S., Lasku A, Marku N. The determination of CA 125 in the serum of Albanian patients with ovarian carcinoma. Journal of the Tumor Marker Oncology. 1994;2:93.
8.
Rada F, Basho J, Buzo S., Marku N, Tavanxhi K, Lasku A. Considerations on the mechanism underlying the increase of serum Thyroxin-binding globulin (TBG) in Acute hepatitis. Balkan Journal of Clinical Laboratory. 1994;1:41–3.
9.
Leskoviku S, Buzo S., Rada F, Lasku A, Marku N. Plasma chromium in diabetics. Balkan Journal of Clinical Laboratory. 1994;1:35–6.
10.
Lasku A, Rada F, Caridha A, Deveja R, Minga G. Serum CEA in lung cancer patients in Albania. Balkan Journal of Clinical Laboratory. 1994;2:56.
11.
Lasku A, Rada F, Buzo S., Marku N, Selenica G. The usefulness of the simultaneous determination of Ca 15-3 and CEA in the early stages patients with mammary carcinoma. Annales de Biologie Clinique. 1993;502.
12.
Leskoviku S, Lasku A, Marku N, Rada F, Dibra A. Usefulness of the determination of carcinoembryonic antigen (CEA) in the serum of patients with colorectal cancer in Albania. Panminerva Med. 1992 Dec;34(4):168–71.
13.
Leskoviku S, Lasku A, Buzo S., Rada F. The determination of CEA in the serum of Albanian patients with colorectal cancer. Journal of the Tumor Marker Oncology. 1992;3:96.
14.
Leskoviku S, Buzo S., Lasku A, Troja K, Rada F. Concentracion plasmatica de cromo (III + VI) en pacientes con diabetes mellitus tipo I. Quimica Clinica. 1991;10:360–2.
15.
Leskoviku S, Buzo S., Lasku A, Rada F. Clinical usefulness of the serum fructosamine measurement in the screening for diabetes mellitus. Biochimica Clinica. 1991;12:1135–7.

Conference Presentations

1.
Rada F., Lasku A. The Clinical Relevance of the Tumor Marker CA 19-9 and CEA in the Diagnosis and Monitoring of Pancreatic Carcinoma and GI Carcinoma. International Congress of Clinical Chemistry. London, UK; 1996.
2.
Mariani G., Lasku A., Pau A., Villa G. Convalida Sperimentale e Clinica dell’Anticorpo Monoclonale BC-1 per la Immunoscintigrafia dei Tumori Cerebrali. National Congress of the Italian Society of Neurosurgery, Anesthesiology and Reanimation. Genoa, Italy; 1996.
3.
Lasku A. The Albanian Experience of the ELISA Method Using Boehringer Mannheim Kits. IFCC European Congress of Clinical Chemistry. Tampere, Finland; 1995.
4.
Leskoviku S., Rada F., Tereska N., Lasku A., Buzo S. The Importance  of Urinary NAG (N- Acetyl-D-Glucosaminidase) in the Discovering of  Renal Tubular Damage. Laboratory Medicine. Capri, Italy; 1993.